Adagio Medical Reports First Quarter 2026 Results and Clinical Progress
Adagio Medical Holdings, Inc., a company specializing in catheter ablation technologies for cardiac arrhythmias, announced its financial results for Q1 2026 and highlighted the pivotal results from the FULCRUM-VT trial presented at the Heart Rhythm Society 2026 conference.
LAGUNA HILLS, Calif.–(BUSINESS WIRE)—- $ADGM #ARRHYTHMIA–Adagio Medical Holdings, Inc (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced financial results for the first quarter ended March 31, 2026. Recent Business Highlights: Pivotal results from the FULCRUM-VT trial presented in late-breaking session at Heart Rhythm Society 2026 – the first large-scale, rigorously executed pivotal trial in patients with bot